000			03402nam a22003375i 4500
999			_c399318 _d399318
001			399318
003			ES-MaUEC
005			20240601174412.0
006			a|||| o|||| 00| 0
007			cr nn 008mamaa
008			231012s2023 sz | o |||| 0|eng d
020			_a9783031328152
024	7		_a10.1007/978-3-031-32815-2 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC394 .H85 _b2023 EB
245	0	0	_aBiomarkers for Huntington's Disease : _bImproving Clinical Outcomes _cedited by Elizabeth A Thomas, Georgia M Parkin
250			_a1st ed. 2023
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aContemporary Clinical Neuroscience _x2627-5341
505	0		_aMolecular Biomarkers.Somatic instability/Telomeres,- Genetic modifiers -- Current clinical trial biomarkers.-Pharmacodynamic biomarkers for Htt-lowering therapeutics.-Inflammatory biomarkers.-Sleep dysregulation markers.-Mitochondrial/Oxidative stress biomarkers.-Microbiomics -- Metabolomics.-Proteomics.-Transcriptomics.-Lipidomics.-Imaging marker overview.-Retinal imaging biomarkers -- MRI - non-invasive functional MRI measures -- The evolution of clinical trial methodology.-Digital biomarkers -- The future of telehealth -- Summary and future trends.
520			_aHuntington's disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of disease; however, current treatments for HD are limited, with only two FDA-approved drugs available to manage chorea. Encouragingly, however, several disease-modifying treatment approaches are in the therapeutic pipeline, with more than 200 clinical studies, and many more preclinical studies, in the works. Robust and reliable biomarkers are needed to predict disease onset, monitor disease progression and assess treatment responses. More specifically, biomarkers to stratify patients for clinical trials and biomarkers to track drug efficacy will certainly lead to improved clinical trial design and success. This book represents the first book focused solely on biomarkers for HD and represents a distinct resource that will be informative, not only for clinicians and those involved in clinical trial design, but also for a wide range of neurodegenerative disease researchers. This edited volume is written by top leaders in the field, and takes a cross-disciplinary approach to cover a broad spectrum of biomarker types, in order to provide the latest advances in the development of biochemical, molecular, imaging and digital biomarkers that have been investigated for HD. With the ultimate goal of treating patients, the development of disease-associated biomarkers has never been more important.
988			_aSpringer_BiomedLife_2023
650		7	_2embne _9158834 _aHuntington, Enfermedad de
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-32815-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b06/2024 _dz _eIG _zSI